A new study has found that drug copayment coupons, while lowering the initial cost to individuals, contribute to higher drug prices overall in the U.S. In one specific category—drugs that treat multiple sclerosis (MS)—the study found that coupons raise negotiated prices by 8% and result in just under $1 billion in increased U.S. pharmaceutical spending annually. The study also estimated that copayment coupons increase spending on couponed drugs without bioequivalent generics by up to 30%.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.